Spotlight On October 2026's Standout Penny Stocks

Over the last 7 days, the U.S. market has risen by 1.2%, contributing to a 13% increase over the past year, with earnings projected to grow by 18% annually in upcoming years. In light of these conditions, investors often seek stocks that combine value and growth potential—qualities that can be found in smaller or newer companies traditionally referred to as penny stocks. Despite being an outdated term, penny stocks remain relevant for those looking for financially strong companies with promising prospects; we'll explore three such standout options below.

We're going to check out a few of the best picks from our screener tool.

Compass Therapeutics (CMPX)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops antibody-based therapeutics for oncology treatment in the United States, with a market cap of $183.69 million.

Operations: No revenue segments are reported for this clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology in the United States.

Market Cap: $183.69M

Compass Therapeutics, Inc. operates as a pre-revenue biopharmaceutical company with a market cap of US$183.69 million, focusing on innovative oncology treatments. Despite being unprofitable, the company has reduced its losses over five years and maintains a solid cash runway exceeding three years. Recent FDA guidance requires further trials for tovecimig in advanced biliary tract cancer, following promising Phase 2/3 results showing improved progression-free survival rates. The management team is relatively new with an average tenure of 1.8 years, but the board is more seasoned at 4.8 years on average. The stock remains highly volatile compared to peers.

• Take a closer look at Compass Therapeutics' potential here in our financial health report.
• Evaluate Compass Therapeutics' prospects by accessing our earnings growth report.

Arq (ARQ)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Arq, Inc. is an environmental technology company that sells consumable air, water, and soil treatment solutions using activated carbon in the United States and Canada, with a market cap of $89.30 million.

Operations: The company's revenue is derived from its Advanced Purification Technologies segment, which generated $123.44 million.

Market Cap: $89.3M

Arq, Inc., with a market cap of US$89.30 million, operates in the environmental technology sector focusing on purification solutions. Despite being unprofitable, it has managed to reduce losses by 30.6% annually over five years and maintains satisfactory short-term financial health with assets exceeding liabilities. The company recently reaffirmed its revenue guidance for 2026 between US$120-125 million, indicating stable business operations despite challenges such as its removal from the S&P Global BMI Index and less than one year of cash runway. Leadership changes include appointing Peter Owino as Chief Accounting Officer to strengthen financial oversight.

• Click here to discover the nuances of Arq with our detailed analytical financial health report.
• Review our growth performance report to gain insights into Arq's future.

Xunlei (XNET)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Xunlei Limited, with a market cap of $306.59 million, operates an internet platform for digital media content in the People's Republic of China through its subsidiaries.

Operations: No specific revenue segments have been reported for this company.

Market Cap: $306.59M

Xunlei Limited, with a market cap of US$306.59 million, has shown significant revenue growth, reporting US$102.11 million for Q2 2026 compared to US$73.6 million the previous year. Despite this, it remains unprofitable with a net loss of US$218.42 million for the same period and a negative return on equity of -9.22%. The company is trading at 44.2% below its estimated fair value and maintains strong financial health with cash exceeding total debt and short-term assets covering both short-term and long-term liabilities comfortably. Recent strategic moves include repurchasing 1,070,000 shares for $5.9 million to potentially enhance shareholder value amidst ongoing challenges in profitability.

• Jump into the full analysis health report here for a deeper understanding of Xunlei.
• Review our historical performance report to gain insights into Xunlei's track record.

Make It Happen

• Investigate our full lineup of 316 US Penny Stocks right here.
• Ready For A Different Approach? We've found 7 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com